PCDHA12

Across TCGA pan-cancer cohorts, PCDHA12 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated PCDHA12 data layer compared with 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PCDHA12 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHA12 expression acts as an unfavorable survival marker, although some lineages such as KIRC and UVM show a favorable association.

LUSC, STAD, and KIRC are the cancer types where PCDHA12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.727	0.823	<.001	114	view →
STAD	OS	Tertile	All	0.605	0.770	<.001	63	view →
KIRC	OS	Median	All	0.864	0.751	<.001	55	view →
UVM	OS	Median	All	0.971	0.651	.001	51	view →
CHOL	DFS	Median	All	0.135	0.749	.003	34	view →
MESO	OS	Tertile	All	0.452	0.221	.016	32	view →
LUAD	OS	Tertile	IV	0.448	0.846	.006	32	view →
UCS	DFS	Tertile	IV	0.936	0.364	.024	26	view →
KICH	DFS	Quartile	II,III,IV	0.621	1.000	.010	20	view →
SCLC	DFS	Tertile	II,III,IV	0.976	0.253	.006	19	view →
HNSC	OS	Tertile	IV	0.501	0.276	.008	19	view →
ESCA	OS	Median	IV	0.222	0.698	.006	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

PCDHA12–LUSC (OS)

Open the LUSC breakdown →